apl. Prof. Dr. Stefan Krause

Medizinische Fakultät Department of Medicine 5 – Haematology and Oncology

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial (2022) Stelljes M, Middeke JM, Bug G, Wagner EM, Mueller LP, Christoph S, Krause S, et al. Conference contribution ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (2022) Ernst T, Schoenfeld L, Rinke J, Hinze A, Nagel SN, Schaefer V, Schenk T, et al. Conference contribution Impact of IDH1 and IDH2 mutational subgroups in acute myeloid leukemia patients after allogeneic hematopoietic cell transplantation (2022) Kunadt D, Stasik S, Metzeler K, Roellig C, Kramer M, Greif P, Spiekermann K, et al. Conference contribution Which factors determine our medical actions? Responsible medicine in the age of tight economic constraints (2022) Combs SE, Krause S, Moesta T, Schmidberger H Journal article, Editorial Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation (2022) Kunadt D, Stasik S, Metzeler KH, Roellig C, Schliemann C, Greif PA, Spiekermann K, et al. Journal article Prophylaxis of bacterial Infections and Pneumocystis jirovecii pneumonia in Female Patients with hematological and oncological Diseases: Updated Guideline of the Working Group on Infections (AGIHO) of the German Society for Hematology and Oncology (DGHO) (2022) Classen AY, Henze L, Von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Duran GL, Alakel N, et al. Conference contribution Reproducibility of measurable residual disease detection by flow cytometry in acute myeloid leukemia (2022) Roehnert MA, Kramer M, Schadt J, Ensel P, Thiede C, Krause S, Buecklein V, et al. Conference contribution ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia (2022) Schoenfeld L, Rinke J, Hinze A, Nagel SN, Schaefer V, Schenk T, Fabisch C, et al. Journal article Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia (2022) Roehnert MA, Kramer M, Schadt J, Ensel P, Thiede C, Krause S, Buecklein V, et al. Journal article Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial (2022) Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, et al. Journal article